2′-Bromo-2′-deoxyuridine
2′-Bromo-2′-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1].
Product Specifications
CAS Number
[4753-02-0]
Product Name Alternative
2'-Bromo-2'-deoxy-D-uridine
UNSPSC
12352005
Hazard Statement
H302, H315, H320, H335
Target
Nucleoside Antimetabolite/Analog
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/2-bromo-2-deoxyuridine.html
Purity
96.92
Solubility
DMSO : 200 mg/mL (ultrasonic)
Smiles
OC[C@@H]1[C@@H](O)[C@@H](Br)[C@H](N2C(NC(C=C2)=O)=O)O1
Molecular Formula
C9H11BrN2O5
Molecular Weight
307.10
Precautions
H302, H315, H320, H335
References & Citations
[1]Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18 (23) :3373-88.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
VSNL1 (Visinin-like Protein 1, VILIP, VLP-1, Hippocalcin-like Protein 3, HLP3, VISL1)
CCL3 (C-C Motif Chemokine 3, G0/G1 Switch Regulatory Protein 19-1, Macrophage Inflammatory Protein 1-alpha, MIP-1-alpha, PAT 464.1, SIS-beta, Small-inducible Cytokine A3, Tonsillar Lymphocyte LD78 alpha Protein, G0S19-1, MIP1A, SCYA3) (MaxLight 490) discontinued
